Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection

J Infect. 2021 Feb;82(2):261-269. doi: 10.1016/j.jinf.2021.01.003. Epub 2021 Jan 10.

Abstract

Objective: To determine the incidence, characteristics, and risk factors of pulmonary embolism (PE) among patients hospitalized for COVID-19.

Patients and methods: We performed a prospective observational study of a randomly selected cohort of consecutive patients hospitalized for COVID-19 infection between March 8, 2020 through April 25, 2020. All eligible patients underwent a computed tomography pulmonary angiography independently of their PE clinical suspicion and were pre-screened for a baseline elevated D-dimer level.

Results: 119 patients were randomly selected from the 372 admitted to one tertiary hospital in Valencia (Spain) for COVID-19 infection during the period of study. Seventy-three patients fulfilled both the inclusion criteria and none of the exclusion criteria and were finally included in the study. Despite a high level of pharmacological thromboprophylaxis (89%), the incidence of PE was 35.6% (95% confidence interval [CI], 29.6 to 41.6%), mostly with a peripheral location and low thrombotic load (Qanadli score 18.5%). Multivariate analysis showed that heart rate (Hazard Ratio [HR], 1.04), room-air oxygen saturation (spO2) (HR, 0.87), D-dimer (HR, 1.02), and C-reactive protein (CRP) levels (HR, 1.01) at the time of admission were independent predictors of incident PE during hospitalization. A risk score was constructed with these four variables showing a high predictive value of incident PE (AUC-ROC: 0.86; 95% CI: 0.80 to 0.93).

Conclusions: Our findings confirmed a high incidence of PE in hospitalized COVID-19 patients. Heart rate, spO2, D-dimer, and CRP levels at admission were associated with higher rates of PE during hospitalization.

Keywords: COVID-19; Computed tomography; Inflammation; Pulmonary embolism; Thrombosis.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Anticoagulants / therapeutic use
  • COVID-19 / complications*
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis
  • Hospitalization
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Prospective Studies
  • Pulmonary Embolism* / epidemiology
  • Risk Factors
  • Spain / epidemiology
  • Venous Thromboembolism* / epidemiology

Substances

  • Anticoagulants
  • Fibrin Fibrinogen Degradation Products